Significance of PBRM1 mutation in disease progress and drug selection in clear cell renal cell carcinoma

by Selleckchem | Nov 02 2023

Clear cell renal cell carcinoma (ccRCC) is the predominant type of kidney cancer, and the mutation of PBRM1 (Polybromo 1) gene is a commonly observed genetic alteration. The high frequency of PBRM1 mutation in ccRCC suggests its potential use as a biomarker for personalized therapy. In this study, we aimed to investigate the significance of PBRM1 mutation in disease progression and drug sensitivity in ccRCC. Additionally, we analyzed the critical pathways and genes associated with PBRM1 mutation to understand its potential mechanisms. Our findings show that PBRM1 mutation was observed in 38% of ccRCC patients and correlated with advanced disease stages. We also identified selective inhibitors for ccRCC with PBRM1 mutation using online databases such as PD173074 and AGI-6780. Furthermore, we identified 1253 genes as differentially expressed genes (DEGs) that were significantly enriched in categories such as metabolic progression, cell proliferation, and development. Although PBRM1 mutation did not show an association with ccRCC prognosis, a lower PBRM1 expression level correlated with worsened prognosis. Our study provides insights into the association of PBRM1 mutation with disease progression in ccRCC and suggests potential gene and signaling pathways for personalized treatment in ccRCC with PBRM1 mutation.

Comments:

Your study focused on investigating the significance of PBRM1 mutation in clear cell renal cell carcinoma (ccRCC) and its implications for disease progression, drug sensitivity, and potential personalized therapy. Here are the key findings from your study:

1. PBRM1 Mutation Frequency: PBRM1 mutation was observed in 38% of ccRCC patients, indicating its high prevalence in this type of kidney cancer.

2. Association with Advanced Disease Stages: The presence of PBRM1 mutation correlated with advanced disease stages, suggesting its involvement in the progression of ccRCC.

3. Identification of Selective Inhibitors: Using online databases such as PD173074 and AGI-6780, you identified selective inhibitors that could be potentially effective for treating ccRCC with PBRM1 mutation.

4. Differentially Expressed Genes (DEGs): Through gene expression analysis, you identified 1253 genes as DEGs associated with PBRM1 mutation. These genes were significantly enriched in categories related to metabolic progression, cell proliferation, and development.

5. Prognostic Implications: While PBRM1 mutation alone did not show a significant association with ccRCC prognosis, a lower expression level of PBRM1 correlated with a worsened prognosis. This suggests that PBRM1 expression level may be a more relevant indicator of disease outcome.

Overall, your study provides valuable insights into the role of PBRM1 mutation in disease progression and its potential implications for personalized treatment in ccRCC. By identifying specific inhibitors and understanding the associated gene and signaling pathways, your findings contribute to the development of targeted therapies for ccRCC patients with PBRM1 mutation.